A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.
Q3 2025 Management View CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing ...
A P rospective rA ndomized tR ial A ssessing the safety and effectiveness of the D urAVR® bI omimetic valve designed for physioloG ic ...
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Biohaven regarding the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ...
Dana Incorporated targets 10–10.5% margins and $1B in shareholder returns by 2027, but execution risk remains high. Read why DAN stock is a Hold.
Q3 2025 Management View Jay Duker, President and CEO, described the quarter as one of “tremendous progress” and highlighted ...
The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.
With so many exciting sporting events happening year-round, it can be tough to know where to stream each one. Thankfully, Fubo should have all your bases covered, no pun intended. Fubo is a live TV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback